Global Vaccine Adjuvants Market is anticipated to grow significantly in the forecast period due to increase in number of infectious diseases. Adjuvants are the formulated vaccines that improve medicinal abilities against infection. They activate the immune systems that allow antigens-pathogens to evoke immune response in the vaccines for long-term protective immunity. Vaccine adjuvants are today considered an important element for maximum clinically used vaccines.
Vaccine adjuvants industry is driven by increasing government focus on durable immunization for the prevalent and emerging diseases, high prevalence of zoonotic and infectious diseases on the global scale, rise in technological advancements, and rise in applications of synthetic and recombinant subunit vaccines. Rise in investments in the research and developments, emphasis on programs for immunization, and increase in demand for the vaccines are also expected to drive the vaccine adjuvants market. However, excess consumption of adjuvants and high cost associated with new product development (development of new vaccine) is expected to hamper the market.
Increase in investment for research and development activities in the domain is trending in the market. Nonetheless, emergence of new diseases on the global scale is expected to offer lucrative opportunities to the vaccine adjuvants industry.
Vaccine adjuvants market is categorized on the basis of administration route, application, disease type, end users, and geography. On the basis of administration route, the market is divided into oral, intranasal, subcutaneous, intradermal, intramuscular, and others. The intramuscular segment is predicted to lead the market due to increase in geriatric population, rise in need for the improved vaccines for better immunization.
Get Sample Copy of this Report @
In terms of application, vaccine adjuvants industry is split into commercial and research application. Research application segments accounted for significant share of the market due to rise in need for better immunization for the growing elderly population and heavy investments for the introduction of better technologies in the domain.
By disease type, the market is divided into cancer, infectious diseases, and other diseases. Infectious disease segment is expected to hold larger share of the market due to increase in cases of diseases and ongoing investment in research for life sciences. Based on end users, the market is bifurcated into veterinary adjuvants and human adjuvants, among which human adjuvants segment leads the market.
Geographically, vaccine adjuvants market is segmented as North America, South America, Europe, Asia Pacific, and Middle East & Africa. North America is predicted to dominate the market in the forecast period due to rise inn investments for research and development activities and rise severe diseases. Asia Pacific region is also expected to lead the market due to constant improvements in healthcare services, growing funding for research and development for meeting the population demands, and availability of medications. Europe and Middle East & Africa are also expected to contribute considerably to the market in future.
The key players in vaccine adjuvants industry include VaxLiant LLC., Brenntag Biosector, Aphios Corporation, Sigma-Aldrich Co. LLC., Viscogel AB, Adjuvatis, Agenus, Inc., Sergeant Adjuvants, MPV Technologies, CureVac AG, Invivogen, Avanti Polar Lipids, Inc., CSL Limited, SEPPIC, Novavax, Inc., SPI Pharma, Inc., OZ Biosciences, and Vaxine Pty Ltd.
Browse Related Category Market Reports @
Comments